Navigation Links
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
Date:5/15/2012

NYSE Amex LLC's letter dated November 26, 2010, as previously reported, and that it had regained compliance with the corresponding requirements of the Exchange.  The Exchange indicated that as with all listed issuers, the Company's continued listing eligibility will continue to be assessed on an ongoing basis and that the Company is subject to the provisions of Section 1009(h) of the NYSE Amex Company Guide, which may be accessed at www.nyse.com/regulation.

During first quarter 2012, the Company completed a registered direct equity financing with three institutional and accredited investors for net proceeds of approximately $4.5 million, after deducting placement agent's fees and estimated offering expenses.  The investors purchased an aggregate of 17.9 million shares of the Company's common stock for a price of $0.28 per share with no warrant coverage.  In addition, during the first quarter, the Company sold 5.2 million shares of common stock in at-the-market transactions for net proceeds of $1.9 million.  Under the terms of the Securities Purchase Agreement dated February 12, 2012, Cardium cannot issue common stock for cash consideration involving a variable rate transaction or issue common stock under its at-the-market sales agreement with Brinson Patrick Securities for a period of six months from the date of the agreement or until the date which our average stock price has exceeded $0.40 for 20 consecutive trading days.

About CardiumCardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations.  Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative m
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium to Present at Upcoming Investor Conferences
2. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
5. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
6. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
7. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
8. Cardium Regains Listing Compliance With NYSE Amex
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
11. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 1000 balances – 4 ... on customers’ weighing needs and expertly narrows down the ... balances, scales or even terminals. , First, select ... weight (or select readability instead) and define the accuracy ... selection criteria narrows down the list to models that ...
(Date:7/24/2014)... Draper University, a top program ... announce that for 6 weeks this summer, 39 ... on the Draper University campus in the heart ... focused on entrepreneurship, building real-world skills, and “learning ... its sixth cohort, continues to refresh its curriculum ...
(Date:7/24/2014)... July 24, 2014   Cypher Genomics, Inc., ... appointment of Adam Simpson as president ... rapid and comprehensive annotation and interpretation of individual ... "Cypher,s technology has the potential to ... enhancing diagnostic accuracy, optimizing therapeutic approaches and reducing ...
(Date:7/24/2014)... San Diego, CA (PRWEB) July 24, 2014 ... in the reporting of molecular diagnostic test results. ... tracking capabilities necessary for the validation and reporting ... in oncology. Molecular diagnostics is a rapidly growing ... for infectious disease, genetic predisposition, cancer, and companion ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... , , , , ... Primer anneal. temp. , Sensitivity , Specifi- , ... Tolerance , of non- , specific RNA , ... of serum components , Carry-over , prevention ...
... amplification of up to 3 kb genomic , DNA targets Cat. No. 1 647 679 ... 647 687 4 x 250 units (1 unit/l) , Cat. No. 1 146 165 100 ... Cat. No. 1 418 432 4 x 250 units (5 units/l) , ... 1 435 094 20 x 250 units (5 units/l) , , , , ...
... , Explore New Horizons in Amplification Yield, , ... High Yield, Accuracy, and the Prevention , of Carry-Over Contamination ... Roche Applied Science, which pioneered the blending , ... Long Template PCR Systems, now introduces the Expand High FidelityPLUS PCR , ...
Cached Biology Technology:Reverse transcriptases suitable for one-step RT-PCRb 2Taq DNA Polymerase 2Taq DNA Polymerase 3Expand High FidelityPLUS PCR System 2Expand High FidelityPLUS PCR System 3
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... scientists from the University of Leicester has published research which ... babies are being exposed to. Research published today ... Edition of Archives of Disease in Childhood documents ... premature infants as part of their medical care. The ...
... technological centre specialising in marine and food research, ... Third country eXpertise) project. The fundamental aim of ... possible on scientific fishery research programs from the ... to achieve effective coordination and cooperation between countries, ...
... suggests that human male fertility is impacted by long-term ... present in the male reproductive tract, further suggesting a ... genetic test to clarify mechanisms. Now, in a paper ... characterize the phenotype of mice genetically lacking FAAH, fatty ...
Cached Biology News:Research exposes the risk to infants from the chemicals used in liquid medicines 2Research exposes the risk to infants from the chemicals used in liquid medicines 3TXOTX, coordinated international project to contribute to sustainability of the marine resources 2February 2009 highlights from Biology of Reproduction 2
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
UGT1A6 (D-20)...
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
... The P5T Series Short Stroke Thrust ... stroke applications where mounting envelopes are limited ... wear bands and internal bumpers provide millions ... applications., Choice of composite bushings or ...
Biology Products: